The Interplay between RNA Editing Regulator ADAR1 and Immune Environment in Colorectal Cancer
Open Access
- 10 January 2023
- journal article
- research article
- Published by Wiley in Journal of Oncology
- Vol. 2023, 1-13
Abstract
An abnormality in the regulation of adenosine deaminase acting on RNA (ADAR) enzymes, which catalyzed adenosine-to-inosine (A-to-I) RNA editing, was closely associated with the highly aggressive biologic behavior and poor prognosis in many malignancies. In the present study, we aimed to investigate the relationship among transcript factors-microRNAs regulatory network, immune environment, and ADAR gene in colorectal carcinoma (CRC). The association among the expression levels of ADAR mRNA and copy number variation, methylation, and mutation status were comprehensively analyzed using cBioPortal, Wanderer, and UALCAN databases in CRC datasets. ADAR-transcript factors (TFs) and ADAR-miRNA regulation networks were constructed by Cistrome Cancer and miRWalk2.0, respectively. The full network and subnetworks for ADAR coexpression genes were constructed using the STRING database and visualized by the MCODE module of the Cytoscape app. The relationship between ADAR mRNA expression and the abundance of infiltrating immune cells in CRC patients was explored by the Tumor Immune Estimation Resource, CIBERSORT, and single-gene gene set enrichment analysis (GSEA). ADAR mRNA was elevated and was a cancer essential gene in CRC. ADAR mRNA and transcripts P110 were significantly elevated in CRC compared to normal controls. Low-level methylation in the promoter region and high copy number amplification of ADAR were responsible for high levels of ADAR mRNA expression. ADAR coexpression genes were mainly involved in immunoregulation, especially T-lymphocyte activation. Hub genes, including CD2, CD274, and FASLG, were also significantly upregulated in the ADAR-high group compared to the control group. Besides, M1 macrophages were enriched in the ADAR-high group compared to the control group. This study demonstrated that ADAR, a new essential gene, was involved in the immune regulator and was a novel immune treatment target in CRC.Keywords
Funding Information
- National Natural Science Foundation of China (2021-ZLLH-06, LD202232)
- Medical engineering cross research fund project of Liaoning Province (2021-ZLLH-06, LD202232)
This publication has 39 references indexed in Scilit:
- Wanderer, an interactive viewer to explore DNA methylation and gene expression data in human cancerEpigenetics & Chromatin, 2015
- Adenosine-to-Inosine RNA Editing Mediated by ADARs in Esophageal Squamous Cell CarcinomaCancer Research, 2014
- ceRNA Cross-Talk in Cancer: When ce-bling Rivalries Go AwryCancer Discovery, 2013
- Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic ValuePLOS Medicine, 2013
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortalScience Signaling, 2013
- The ADAR protein familyGenome Biology, 2012
- Origins and evolution of ADAR‐mediated RNA editingIUBMB Life, 2009
- Altered adenosine-to-inosine RNA editing in human cancerGenome Research, 2007
- Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction NetworksGenome Research, 2003
- Molecular cloning of cDNA for double-stranded RNA adenosine deaminase, a candidate enzyme for nuclear RNA editing.Proceedings of the National Academy of Sciences, 1994